Additionally, in chronic leukemias such as CLL, NGS is useful at treatment initiation and disease progression, particularly for identifying TP53 mutations, which predict poor response to chemoimmunotherapy and favor the use of targeted agents like BTK inhibitors [182,183]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.